Format

Send to

Choose Destination
J Autoimmun. 2014 May;50:135-41. doi: 10.1016/j.jaut.2014.03.002. Epub 2014 Apr 2.

Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.

Author information

1
National Referral Center for Rare Systemic Autoimmune Diseases, Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Division of Rheumatology, University of São Paulo School of Medicine, São Paulo, Brazil.
2
National Referral Center for Rare Systemic Autoimmune Diseases, Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France. Electronic address: xavier.puechal@cch.aphp.fr.
3
National Referral Center for Rare Systemic Autoimmune Diseases, Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Service de Médecine Interne, CHU Purpan, Toulouse, France.
4
National Referral Center for Rare Systemic Autoimmune Diseases, Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France.
5
National Referral Center for Rare Systemic Autoimmune Diseases, Service de Médecine Interne, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris Descartes, Paris, France; Institut Cochin, INSERM U1016, CNRS UMR 8104, Paris, France.

Abstract

The aim of this study was to evaluate the efficacy and safety of rituximab (RTX) associated with glucocorticoid treatment based on disease severity, as a remission induction treatment for granulomatosis with polyangiitis (GPA) (Wegener's) and to analyze the results of long-term maintenance therapy with low doses of RTX in a routine time-based protocol. This single-center retrospective study used standardized data collection from all GPA patients receiving RTX between 2002 and 2013. The remission induction regimen consisted of RTX and glucocorticoids, adapted according to disease severity. Once remission was achieved, patients received RTX maintenance treatment (500 mg every 6 months) for 18 months. Sixty-six GPA patients received RTX for remission induction. After six months, a response had been achieved in 78.8% of these patients, with a moderate oral prednisone regimen (mean dose at baseline, 32.8 ± 23.4 mg/day). Subglottic stenosis increased the risk of treatment failure (OR = 31.2, P = 0.0104). RTX maintenance treatment was continued for 18 months in 92% of the GPA patients, who were followed for 34.2 ± 26.2 months (mean total cumulative RTX dose of 4.6 ± 1.7 g). The relapse rate was 11.2/100 patient-years. The relapses occur a mean of 13.5 ± 14.7 months after the last RTX infusion. Twenty-one severe adverse events were recorded; 13.6% patients had severe infections. We conclude that in this single-center cohort, RTX associated with glucocorticoid treatment adapted for disease severity appeared to induce remission effectively in GPA patients. Maintenance treatment with low doses of RTX in a routine time-based protocol was safe and associated with low rates of relapse on treatment.

KEYWORDS:

ANCA-associated vasculitis; Glucocorticoids; Granulomatosis with polyangiitis; Maintenance; Remission induction treatment; Rituximab

PMID:
24703438
DOI:
10.1016/j.jaut.2014.03.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center